CHW affiliate Yibin Kang has received an award from Princeton’s Intellectual Property Accelerator Fund, which offers seed money for innovations with the potential to solve today’s most pressing problems. Kang and his team are developing a small-molecule inhibitor that could significantly enhance the efficacy of existing immunotherapies against a broad spectrum of human cancers.